Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 207,279 | 159,933 | 166,496 | 139,292 | 164,647 |
| Cost of Goods | 29,345 | 27,991 | 23,002 | 28,662 | 17,166 |
| Gross Profit | 177,934 | 131,942 | 143,494 | 110,630 | 147,481 |
| Operating Expenses | 291,562 | 303,823 | 251,384 | 254,231 | 269,952 |
| Operating Income | -113,283 | -170,890 | -107,888 | -142,939 | -122,305 |
| Interest Expense | 19,469 | 14,148 | 14,041 | 14,342 | 15,481 |
| Other Income | 5,066 | 5,498 | 7,925 | 7,511 | 4,968 |
| Pre-tax Income | -127,686 | -179,540 | -114,004 | -149,770 | -132,818 |
| Income Tax | 870 | 873 | 947 | 1,310 | 384 |
| Net Income Continuous | -128,556 | -180,413 | -114,951 | -151,080 | -133,202 |
| Net Income | $-128,556 | $-180,413 | $-114,951 | $-151,080 | $-133,202 |
| EPS Basic Total Ops | -1.28 | -1.81 | -1.17 | -1.57 | -1.34 |
| EPS Basic Continuous Ops | -1.29 | -1.81 | -1.17 | -1.57 | -1.34 |
| EPS Diluted Total Ops | -1.28 | -1.81 | -1.17 | -1.57 | -1.34 |
| EPS Diluted Continuous Ops | -1.29 | -1.81 | -1.17 | -1.57 | -1.34 |
| EPS Diluted Before Non-Recurring Items | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 |
| EBITDA(a) | $-105,014 | $-162,988 | $-100,316 | $-135,682 | $-115,951 |